Barry G. Arnason to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Barry G. Arnason has written about Dose-Response Relationship, Drug.
Connection Strength
0.089
-
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
Score: 0.023
-
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
Score: 0.022
-
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
Score: 0.014
-
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
Score: 0.013
-
Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62.
Score: 0.009
-
Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci U S A. 1979 Sep; 76(9):4632-5.
Score: 0.007